Evidence map›Paper›PMID 30626882›Full record

ArticleScientific reports2019

The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α

D Nakladal, H Buikema, A Reyes Romero, S P H Lambooy, J Bouma, G Krenning, P Vogelaar, A C van der Graaf, M R Groves, J Kyselovic and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

D NakladalDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
H BuikemaDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
A Reyes RomeroDepartment of Drug Design, School of Pharmacy, University of Groningen, Antonius Deusinglaan 1 Postbus 196, 9700 AD, Groningen, The Netherlands.
S P H LambooyDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
J BoumaDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
G KrenningCardiovascular Regenerative Medicine, Dept. Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-5850-5667
P VogelaarSulfateq B.V., Admiraal de Ruyterlaan 5, 9726GN, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-8271-3204
A C van der GraafSulfateq B.V., Admiraal de Ruyterlaan 5, 9726GN, Groningen, The Netherlands.
M R GrovesDepartment of Drug Design, School of Pharmacy, University of Groningen, Antonius Deusinglaan 1 Postbus 196, 9700 AD, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-9859-5177
J Kyselovic5th Department of Internal Medicine, Faculty of Medicine, University Hospital, Commenius University, Bratislava, Slovak Republic.
R H HenningDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
L E DeelmanDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. l.e.deelman@umcg.nl.
University Medical Center Groningen · NLUniversity of Groningen · NLComenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SUL-compounds are protectants from cold-induced ischemia and mitochondrial dysfunction. We discovered that adding SUL-121 to renal grafts during warm machine reperfusion elicits a rapid improvement in perfusion parameters. Therefore, we investigate the molecular mechanisms of action in porcine intrarenal arteries (PIRA). Porcine kidneys were stored on ice overnight and perfusion parameters were recorded during treatment with SUL-compounds. Agonist-induced vasoconstriction was measured in isolated PIRA after pre-incubation with SUL-compounds. Receptor binding and calcium transients were assessed in α

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAnimalsCHO CellsChromansCricetulusKidneyPiperazinesReceptors, Adrenergic, alpha-1ReperfusionSwineVasoconstrictionAdrenergic alpha-1 Receptor AntagonistsChromansPiperazinesReceptors, Adrenergic, alpha-1Sul-121

Identifiers

PMID30626882
PMCPMC6327096
OpenAlexW2910591827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.